164 related articles for article (PubMed ID: 15359586)
1. Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-Polycaprolactone amphiphilic diblock copolymers.
Zastre J; Jackson J; Burt H
Pharm Res; 2004 Aug; 21(8):1489-97. PubMed ID: 15359586
[TBL] [Abstract][Full Text] [Related]
2. Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity.
Zastre J; Jackson JK; Wong W; Burt HM
J Pharm Sci; 2007 Apr; 96(4):864-75. PubMed ID: 17094135
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers.
Zastre J; Jackson J; Bajwa M; Liggins R; Iqbal F; Burt H
Eur J Pharm Biopharm; 2002 Nov; 54(3):299-309. PubMed ID: 12445560
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity.
Zastre JA; Jackson JK; Wong W; Burt HM
Mol Pharm; 2008; 5(4):643-53. PubMed ID: 18380467
[TBL] [Abstract][Full Text] [Related]
5. Same-single-cell analysis using the microfluidic biochip to reveal drug accumulation enhancement by an amphiphilic diblock copolymer drug formulation.
Khamenehfar A; Wan CP; Li PC; Letchford K; Burt HM
Anal Bioanal Chem; 2014 Nov; 406(28):7071-83. PubMed ID: 25315452
[TBL] [Abstract][Full Text] [Related]
6. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Elamanchili P; McEachern C; Burt H
J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
[TBL] [Abstract][Full Text] [Related]
8. The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells.
Jackson J; Leung D; Burt H
Ultrasonics; 2020 Feb; 101():106033. PubMed ID: 31561207
[TBL] [Abstract][Full Text] [Related]
9. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers.
Annaert P; Van Gelder J; Naesens L; De Clercq E; Van den Mooter G; Kinget R; Augustijns P
Pharm Res; 1998 Aug; 15(8):1168-73. PubMed ID: 9706045
[TBL] [Abstract][Full Text] [Related]
10. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1192-9. PubMed ID: 12948017
[TBL] [Abstract][Full Text] [Related]
11. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone.
Wu SJ; Robinson JR
Pharm Res; 1999 Aug; 16(8):1266-72. PubMed ID: 10468030
[TBL] [Abstract][Full Text] [Related]
12. Mixed molecular weight copolymer nanoparticles for the treatment of drug-resistant tumors: formulation development and cytotoxicity.
Wan CPL; Letchford K; Leung D; Jackson JK; Burt HM
J Pharm Sci; 2014 Dec; 103(12):3966-3976. PubMed ID: 25318668
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
14. Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 cell culture model.
Hu M; Chen J
Mol Pharm; 2004; 1(3):194-200. PubMed ID: 15981922
[TBL] [Abstract][Full Text] [Related]
15. Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity.
Li W; Li X; Gao Y; Zhou Y; Ma S; Zhao Y; Li J; Liu Y; Wang X; Yin D
Mol Pharm; 2014 Jan; 11(1):71-80. PubMed ID: 24256068
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
17. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
19. A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell.
Ho NF; Burton PS; Conradi RA; Barsuhn CL
J Pharm Sci; 1995 Jan; 84(1):21-7. PubMed ID: 7714738
[TBL] [Abstract][Full Text] [Related]
20. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
